Volume 16, Issue 3 (Autumn 2021)                   Salmand: Iranian Journal of Ageing 2021, 16(3): 426-437 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Talebi Moghaddam M, Bakhshi E, Amini E, Nowroozi M R, Vahedi M. Effects of Admission Age and Gleason Score on the State Transition in Elderly Patients With Prostate Cancer Using a Multi-State Model. Salmand: Iranian Journal of Ageing. 2021; 16 (3) :426-437
URL: http://salmandj.uswr.ac.ir/article-1-1858-en.html
1- Department of Biostatistics and Epidemiology, Faculty of Rehabilitation Sciences, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
2- Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
3- Department of Biostatistics and Epidemiology, Faculty of Rehabilitation Sciences, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. , mo.vahedi@uswr.ac.ir
Abstract:   (3770 Views)
Objectives: Cancer is one of the leading causes of death among the elderly in the world. There are several factors involved in the development and progression of cancer. Therefore, knowing these factors and how they affect the cancer patient’s process can help in timely treatment of the disease. This study aims to evaluate the effects of admission age and Gleason score on the state transition in elderly patients with prostate cancer.
Methods & Materials: This is a historic cohort study conducted in 2018. The studied data are related to 125 elderly patients with prostate cancer (Mean±SD age= 72.12±7.32 years) who referred to the urology department of Imam Khomeini Hospital from 2004 to 2017 and underwent radical prostatectomy and were under different conditions (Radiation therapy, hormone therapy, or death) after surgery. The effect of admission age and Gleason score on the transition between states were tested using a multi-state model in R v.5.0 software.
Results: Those who underwent surgery and treatment remained 4.5 years in the local recurrence state, 2 years in the distant recurrence state, and 6.5 years in the death state. People who had surgery were 17% more likely to metastasize and accept hormone therapy; 8.8% more likely to have a local recurrence and accept radiotherapy; and 8% more likely to experience death. The effect of Gleason score on the change of state was not significant, but the age variable was effective transition from surgical state to hormone therapy.
Conclusion: In elderly patients who have undergone radical prostatectomy, the risk of metastasis increases with age.
Full-Text [PDF 3785 kb]   (973 Downloads) |   |   Full-Text (HTML)  (146 Views)  
Type of Study: Applicable | Subject: gerontology
Received: 2019/07/09 | Accepted: 2019/12/08 | Published: 2021/10/01

References
1. 1Sahaf R, Khankeh HR, Abolfathi Momtaz Y, Hamedanchi A. Content Analysis of the Topics of Ageing-related Theses at the University of Social Welfare and Rehabilitation Sciences in Iran. Salmand: Iranian Journal of Ageing. 2018;13(3):300-11. eng. [DOI:10.32598/sija.13.3.300]
2. 2Rasel M, Ardalan A. The Future of Ageing and Its Health Care Costs: A Warning for Health System. Salmand: Iranian Journal of Ageing. 2007;2(2):300-5. eng.
3. 3Hughes R, Kleinpell M. Fletcher k. Patient safety and quality an evidence-based Hand Book for Nurses. Kleinpell M, Fletcher k, Jennings BM reducing functional decline in hospitalized elderly 9thed New York: AHRQ. 2009:251-65.
4. 4Lewis CL, Kistler CE, Amick HR, Watson LC, Bynum DL, Walter LC, et al. Older adults' attitudes about continuing cancer screening later in life: a pilot study interviewing residents of two continuing care communities. BMC Geriatr. 2006;6(1):10. [DOI:10.1186/1471-2318-6-10] [PMID] [PMCID]
5. 5Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol. 2011;174(7):860-70. [DOI:10.1093/aje/kwr146] [PMID] [PMCID]
6. 6Sadjadi A, Nooraie M, Ghorbani A, Alimohammadian M, Zahedi M-J, Darvish-Moghadam S, et al. The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med. 2007;10(4):481-5.
7. 7Pourmand G, Allameh F, Mohammad K, Dehghani S, Pourmand B, Mehrsai A, et al. Prostate cancer predicting factors: a preliminary report from Tehran. Urology journal. 2012;9(4):667-72.
8. 8Hassanipour S, Fathalipour M, Salehiniya H. The incidence of prostate cancer in Iran: a systematic review and meta-analysis. Prostate International. 2018;6(2):41-5. [DOI:10.1016/j.prnil.2017.11.003] [PMID] [PMCID]
9. 9Pakzad R, Rafiemanesh H, Ghoncheh M, Sarmad A, Salehiniya H, Hosseini S, et al. Prostate cancer in Iran: trends in incidence and morphological and epidemiological characteristics. Asian Pac J Cancer Prev. 2016;17(2):839-43. [DOI:10.7314/APJCP.2016.17.2.839] [PMID]
10. 10Jewett MA, Fleshner N, Klotz LH, Nam RK, Trachtenberg J. Radical prostatectomy as treatment for prostate cancer. Can Med Assoc J. 2003;168(1):44-5.
11. 11Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000;18(23):3904-11. [DOI:10.1200/JCO.2000.18.23.3904] [PMID]
12. 12Damber J-E, Aus G. Prostate cancer. The Lancet. 2008;371(9625):1710-21. [DOI:10.1016/S0140-6736(08)60729-1]
13. 13Kehinde EO, Mojiminiyi OA, Sheikh M, Al‐Awadi KA, Daar AS, Al‐Hunayan A, et al. Age‐specific reference levels of serum prostate‐specific antigen and prostate volume in healthy Arab men. BJU international. 2005;96(3):308-12. [DOI:10.1111/j.1464-410X.2005.05620.x] [PMID]
14. 14Yu M, Law NJ, Taylor JM, Sandler HM. Joint longitudinal-survival-cure models and their application to prostate cancer. Statistica Sinica. 2004:835-62.
15. 15Jackson CH. Multi-state models for panel data: the msm package for R. Journal of Statistical Software. 2011;38(8):1-29. [DOI:10.18637/jss.v038.i08]
16. 16Meira-Machado L, de Uña-Álvarez J, Cadarso-Suárez C, Andersen PK. Multi-state models for the analysis of time-to-event data. Stat Methods Med Res. 2009;18(2):195-222. [DOI:10.1177/0962280208092301] [PMID] [PMCID]
17. 17Galvin A, Helmer C, Coureau G, Amadeo B, Joly P, Sabathé C, et al. Determinants of cancer treatment and mortality in older cancer patients using a multi-state model: Results from a population-based study (the INCAPAC study). Cancer Epidemiol. 2018;55:39-44. [DOI:10.1016/j.canep.2018.04.013] [PMID]
18. 18Ferrer L, Rondeau V, Dignam J, Pickles T, Jacqmin‐Gadda H, Proust‐Lima C. Joint modelling of longitudinal and multi‐state processes: application to clinical progressions in prostate cancer. Stat Med. 2016;35(22):3933-48. [DOI:10.1002/sim.6972] [PMID] [PMCID]
19. 19Beesley LJ, Morgan TM, Spratt DE, Singhal U, Feng FY, Furgal AC, et al. Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. JAMA network open. 2019;2(2):e187765-e. [DOI:10.1001/jamanetworkopen.2018.7765] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Iranian Journal of Ageing

Designed & Developed by : Yektaweb